Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Next-Generation Coronary Stent Start-Ups: Making a Difference in a Mature Market

This article was originally published in Start Up

Executive Summary

Which kinds of innovations make for incremental enhancements in the hands of large companies and which are meaningful enough to sustain a venture-backed start-up company? In a mature market for coronary stents dominated by large companies, start-ups developing new stents need to find the answers. Areas of innovation fall into four basic categories: improving stent safety and biocompatibility, avoiding the need for dual antiplatelet therapy, enhancing deliverability, and introducing specialty stents for complex vessels. Three companies profiled here have a plan for taking sufficient market share, reducing risk, and rewarding investors.

You may also be interested in...

The Future of Drug-Eluting Stents Part I: Novel Next-Generation Designs

Growth by innovation is almost considered a birthright in interventional cardiology, and based on presentations at this year's Transcatheter Cardiovascular Therapeutics meeting, held this September in San Francisco, it seems clear that innovation still reigns supreme in this specialty. However, as in other medical device markets, ongoing economic and regulatory pressures are taking their toll, particularly in the drug-eluting stent market, as the field adjusts to a new era of cost control and economic uncertainty.

Stent Market Doldrums Push Interest Elsewhere

The new realities of the drug-eluting stent market are evident in recent sales results from the big competitors, driving many of them to branch into other higher growth areas.

Boston Scientific Looks to Next-Generation DES with Labcoat Deal

Boston Scientific's unique two-drug strategy has propelled the company to a leadership position in drug-eluting stents with, according to some estimates, more than 50% of the market. Yet the company is not relying on the current configurations of or the current manufacturing approaches for its Taxus (using paclitaxel) and Promus (which employs everolimus) stents to sustain its position on top of this highly competitive product area. With its acquisition this month of Galway, Ireland-based Labcoat Ltd. (terms of which were not disclosed), BSC is laying the groundwork for technology that may well define its next generation of drug-eluting stents.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts